About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Romosozumab
- Company
- UCB Biopharma SRL
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- 10 recruiting
Efficacy results: Not yet reported
10 recruiting studies currently listed on ClinicalTrials.gov.
Data source: ClinicalTrials.gov · trial data as of Sep 29, 2026
Find a Clinical Trial Near Me
See recruiting studies for Romosozumab and check eligibility with the study team.
Trial details
-
Recruiting NCT NCT05688969
Mechanisms of Anabolic Osteoporosis Therapy
Not yet reported Massachusetts General Hospital 16 participants Est. completion 2028-12 1 siteOther conditions: Osteoporosis, PostmenopausalView official trial listing → -
Recruiting NCT NCT06059222
The Optimised Use of Romozosumab Study
Not yet reported University of Aarhus 270 participants Est. completion 2032-08-31 1 siteOther conditions: OsteoporosisView official trial listing → -
Recruiting NCT NCT06164795
Sequential Therapies After Osteoanabolic Treatment
424 General Military Hospital 150 participants Est. completion 2027-12 8 sitesOther conditions: Osteoporosis, PostmenopausalView official trial listing → -
Recruiting NCT NCT06533865
Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea
Not yet reported Massachusetts General Hospital 114 participants Est. completion 2029-04 2 sites Stand-aloneOther conditions: FHA (Functional Hypothalamic Amenorrhea)View official trial listing → -
Recruiting NCT NCT06558188
Combined Anabolic Therapy
Not yet reported Massachusetts General Hospital 50 participants Est. completion 2028-04-01 1 siteOther conditions: Osteoporosis, Postmenopausal, OsteoporosisView official trial listing → -
Recruiting NCT NCT06938152
Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients
Not yet reported National Taiwan University Hospital 70 participants Est. completion 2029-12-31 1 site Stand-aloneOther conditions: Osteoporosis, Osteoporosis PostmenopausalView official trial listing → -
Recruiting NCT NCT07283887
Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis
Not yet reported National Taiwan University Hospital 90 participants Est. completion 2026-07-31 1 site Stand-aloneOther conditions: OsteoporosisView official trial listing → -
Recruiting NCT NCT07366086
Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta
Not yet reported Amgen 71 participants Est. completion 2028-04-19 4 sitesOther conditions: Osteogenesis ImperfectaView official trial listing → -
Recruiting NCT NCT07616401
MicroRNA and Markers and Therapeutic Response to Romosozumab and Abaloparatide in Postmenopausal Osteoporosis
Not yet reported Istituto Auxologico Italiano 42 participants Est. completion 2029-08-31 2 sites Stand-aloneOther conditions: Osteoporosis, MenopauseView official trial listing → -
Recruiting NCT NCT07776613
A Study of Romosozumab in People With Breast Cancer and Osteoporosis
Not yet reported Memorial Sloan Kettering Cancer Center 25 participants Est. completion 2028-08 7 sites Stand-aloneOther conditions: Breast Cancer, Metastatic Breast Cancer (MBC)View official trial listing → -
Completed NCT NCT00896532
Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
Not yet reported Amgen 419 participants Est. completion 2016-02-18 Stand-aloneOther conditions: Low Bone Mineral Density, Postmenopausal OsteoporosisView official trial listing → -
Completed NCT NCT00907296
Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing
Not yet reported Amgen 402 participants Est. completion 2013-05-10 103 sites Stand-aloneOther conditions: Fracture HealingView official trial listing → -
Completed NCT NCT00950950
A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass
Not yet reported Amgen 24 participants Est. completion 2010-08-19 Stand-aloneOther conditions: OsteopeniaView official trial listing → -
Completed NCT NCT01059435
A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal Women
Not yet reported Amgen 74 participants Est. completion 2007-07-06 Stand-aloneOther conditions: OsteopeniaView official trial listing → -
Completed NCT NCT01081678
Study To Assess FRacTure Healing With SclerosTin Antibody - Hip
Not yet reported Amgen 332 participants Est. completion 2013-05-10 99 sites Stand-aloneOther conditions: Fracture HealingView official trial listing → -
Completed NCT NCT01101061
A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women
Not yet reported Amgen 31 participants Est. completion 2010-11-01 Stand-aloneOther conditions: OsteopeniaView official trial listing → -
Completed NCT NCT01575834
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Not yet reported Amgen 7180 participants Est. completion 2016-12-28 218 sites Stand-aloneOther conditions: Postmenopausal OsteoporosisView official trial listing → -
Completed NCT NCT01588509
Transition From Alendronate to Romosozumab (AMG 785)
Not yet reported Amgen 60 participants Est. completion 2012-11-21 9 sites Stand-aloneOther conditions: OsteoporosisView official trial listing → -
Completed NCT NCT01631214
Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis
Not yet reported Amgen 4093 participants Est. completion 2017-06-29 316 sites Stand-aloneOther conditions: Postmenopausal Women With OsteoporosisView official trial listing → -
Completed NCT NCT01796301
An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
Not yet reported Amgen 436 participants Est. completion 2015-05-14 50 sites Stand-aloneOther conditions: Postmenopausal OsteoporosisView official trial listing → -
Completed NCT NCT01825785
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)
Not yet reported Amgen 48 participants Est. completion 2008-12-02 Stand-aloneOther conditions: Postmenopausal, OsteopeniaView official trial listing → -
Completed NCT NCT01833754
Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
Not yet reported Amgen 24 participants Est. completion 2014-02-19 5 sites Stand-aloneOther conditions: OsteoporosisView official trial listing → -
Completed NCT NCT01992159
Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis
Not yet reported Amgen 252 participants Est. completion 2015-06-17 27 sites Stand-aloneOther conditions: Postmenopausal Osteoporosis (PMO)View official trial listing → -
Completed NCT NCT02016716
A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis
Not yet reported Amgen 294 participants Est. completion 2014-12-08 12 sites Stand-aloneOther conditions: Postmenopausal OsteoporosisView official trial listing → -
Completed NCT NCT02186171
A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis
Not yet reported Amgen 245 participants Est. completion 2016-04-20 34 sites Stand-aloneOther conditions: Osteoporosis in MenView official trial listing → -
Completed NCT NCT02791516
A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis
Not yet reported Amgen 67 participants Est. completion 2018-12-21 10 sites Stand-aloneOther conditions: Postmenopausal OsteoporosisView official trial listing → -
Completed NCT NCT03432533
A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis
Not yet reported Amgen 283 participants Est. completion 2020-01-08 46 sitesOther conditions: Post-Menopausal OsteoporosisView official trial listing → -
Completed NCT NCT04091243
Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users
Not yet reported Tuen Mun Hospital 70 participants Est. completion 2023-11-15 1 site Stand-aloneOther conditions: Glucocorticoid-induced OsteoporosisView official trial listing → -
Completed NCT NCT04232657
Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
Not yet reported VA Office of Research and Development 36 participants Est. completion 2026-08-24 2 sites Stand-aloneOther conditions: Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCIView official trial listing → -
Completed NCT NCT04545554
Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta
Not yet reported Amgen 25 participants Est. completion 2023-03-30 15 sites Stand-aloneOther conditions: Osteogenesis ImperfectaView official trial listing → -
Status unknown NCT NCT04597931
Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density
Not yet reported Sheba Medical Center 30 participants Est. completion 2023-11-15 Stand-aloneOther conditions: Osteoporosis Fracture, Spinal Cord InjuriesView official trial listing → -
Completed NCT NCT04708886
Romosozumab in Women With Chronic SCI
Not yet reported Northwestern University 12 participants Est. completion 2024-06-10 1 site Stand-aloneOther conditions: Osteoporosis, Bone Loss, Osteopenia, Osteoporosis, Spinal Cord Injuries, Chronic Spinal ParalysisView official trial listing → -
Completed NCT NCT04779216
Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa
Not yet reported Karen Klahr Miller, MD 30 participants Est. completion 2025-11-17 1 site Stand-aloneObstructive sleep apnea Other conditions: Bone Density, Low, Bone Loss, Eating DisordersView official trial listing → -
Active, not recruiting NCT NCT04800367
Romosozumab/Denosumab Study for Premenopausal IOP
Not yet reported Columbia University 30 participants Est. completion 2028-03 1 site Stand-aloneOther conditions: Premenopausal Idiopathic OsteoporosisView official trial listing → -
Active, not recruiting NCT NCT05010590
Anabolic Therapy in Postmenopausal Osteoporosis
Not yet reported Massachusetts General Hospital 50 participants Est. completion 2027-11-01 1 siteOther conditions: Postmenopausal OsteoporosisView official trial listing → -
Active, not recruiting NCT NCT05058976
Romosozumab Use to Build Skeletal Integrity
Not yet reported Susan L. Greenspan 184 participants Est. completion 2027-03-31 1 site Stand-aloneOther conditions: Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis FractureView official trial listing → -
Completed NCT NCT05067335
A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis
Not yet reported UCB Biopharma SRL 327 participants Est. completion 2023-11-09 30 sites Stand-aloneOther conditions: OsteoporosisView official trial listing → -
Active, not recruiting NCT NCT05101018
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
Not yet reported James J. Peters Veterans Affairs Medical Center 40 participants Est. completion 2027-11-01 2 sites Stand-aloneOther conditions: Osteoporosis, Spinal Cord InjuriesView official trial listing → -
Active, not recruiting NCT NCT05775094
A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis
Not yet reported Memorial Sloan Kettering Cancer Center 10 participants Est. completion 2027-03 7 sites Stand-aloneOther conditions: Osteoporosis, Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT05972551
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
Not yet reported Amgen 111 participants Est. completion 2027-07-30 65 sites Stand-aloneOther conditions: Osteogenesis ImperfectaView official trial listing → -
Completed NCT NCT06079476
A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
Not yet reported Amgen 100 participants Est. completion 2025-10-18 10 sites Stand-aloneOther conditions: Postmenopausal OsteoporosisView official trial listing → -
Completed NCT NCT06472050
Romosozumab Versus Denosumab in Glucocorticoid-induced Osteoporosis: an Extended Observation of a Randomized Controlled Trial at 48 Months
Not yet reported Tuen Mun Hospital 54 participants Est. completion 2026-04-30 1 siteOther conditions: Osteoporosis, Glucocorticoids ToxicityView official trial listing → -
Not yet recruiting NCT NCT06720350
Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures
Not yet reported Marmara University 60 participants Est. completion 2026-12-15 1 site Stand-aloneOther conditions: Osteoporosis in Post-menopausal WomenView official trial listing → -
Enrolling by invitation NCT NCT06811363
Contribution of Bone to Urine Citrate
University of Texas Southwestern Medical Center 25 participants Est. completion 2027-03 1 siteOther conditions: OsteoporosisView official trial listing → -
Withdrawn NCT NCT06973109
Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes
Not yet reported University of Pittsburgh Est. completion 2027-06 1 site Stand-aloneOther conditions: Osteoporosis, Post-menopausalView official trial listing → -
Enrolling by invitation NCT NCT07384104
Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy Subjects
Not yet reported Shenzhen Salubris Pharmaceuticals Co., Ltd. 118 participants Est. completion 2026-02-05 1 siteOther conditions: OsteoporosisView official trial listing → -
Not yet recruiting NCT NCT07757373
Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 Years
Not yet reported Tuen Mun Hospital 54 participants Est. completion 2027-12-01 1 siteOther conditions: Glucocorticoid-Associated Osteopenia and OsteoporosisView official trial listing → -
Not yet recruiting NCT NCT07772609
Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD
Not yet reported Sahlgrenska University Hospital 216 participants Est. completion 2031-12-31 9 sites Stand-aloneOther conditions: Osteoporosis in Post-menopausal WomenView official trial listing → -
Not yet recruiting NCT NCT07811999
Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections
Not yet reported Amgen 308 participants Est. completion 2027-01-14 Stand-aloneOther conditions: Healthy ParticipantsView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Also known as: Romosozumab, Evenity
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.